Sunshine Biopharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.35
- Today's High:
- $0.38
- Open Price:
- $0.38
- 52W Low:
- $0.35
- 52W High:
- $1.47
- Prev. Close:
- $0.382
- Volume:
- 142582
Company Statistics
- Market Cap.:
- $9.85 million
- Book Value:
- 0.898
- Revenue TTM:
- $14.53 million
- Operating Margin TTM:
- -65.9%
- Gross Profit TTM:
- $1.70 million
- Profit Margin:
- -189.8%
- Return on Assets TTM:
- -17%
- Return on Equity TTM:
- -84.85%
Company Profile
Sunshine Biopharma Inc had its IPO on 2009-10-30 under the ticker symbol SBFM.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Sunshine Biopharma Inc has a staff strength of 46 employees.
Stock update
Shares of Sunshine Biopharma Inc opened at $0.38 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.35 - $0.38, and closed at $0.36.
This is a -7.07% slip from the previous day's closing price.
A total volume of 142,582 shares were traded at the close of the day’s session.
In the last one week, shares of Sunshine Biopharma Inc have slipped by -15.07%.
Sunshine Biopharma Inc's Key Ratios
Sunshine Biopharma Inc has a market cap of $9.85 million, indicating a price to book ratio of 0.3957 and a price to sales ratio of 31.3884.
In the last 12-months Sunshine Biopharma Inc’s revenue was $14.53 million with a gross profit of $1.70 million and an EBITDA of $-9484115. The EBITDA ratio measures Sunshine Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sunshine Biopharma Inc’s operating margin was -65.9% while its return on assets stood at -17% with a return of equity of -84.85%.
In Q2, Sunshine Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 3599.7%.
Sunshine Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sunshine Biopharma Inc’s profitability.
Sunshine Biopharma Inc stock is trading at a EV to sales ratio of 32.4651 and a EV to EBITDA ratio of -6.3589. Its price to sales ratio in the trailing 12-months stood at 31.3884.
Sunshine Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $28.41 million
- Total Liabilities
- $4.66 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $294230
- Dividend Payout Ratio
- 0%
Sunshine Biopharma Inc ended 2024 with $28.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $28.41 million while shareholder equity stood at $23.11 million.
Sunshine Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $4.66 million in other current liabilities, 25746.00 in common stock, $-62004152.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.73 million and cash and short-term investments were $19.73 million. The company’s total short-term debt was $122,146 while long-term debt stood at $0.
Sunshine Biopharma Inc’s total current assets stands at $26.10 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.01 million compared to accounts payable of $1.76 million and inventory worth $4.25 million.
In 2024, Sunshine Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $294230.
Comparatively, Sunshine Biopharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.36
- 52-Week High
- $1.47
- 52-Week Low
- $0.35
- Analyst Target Price
- $3
Sunshine Biopharma Inc stock is currently trading at $0.36 per share. It touched a 52-week high of $1.47 and a 52-week low of $1.47. Analysts tracking the stock have a 12-month average target price of $3.
Its 50-day moving average was $0.47 and 200-day moving average was $0.68 The short ratio stood at 1.9 indicating a short percent outstanding of 0%.
Around 1858.1% of the company’s stock are held by insiders while 183.5% are held by institutions.
Frequently Asked Questions About Sunshine Biopharma Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.